News
Novo to part ways with longtime CEO Lars Fruergaard Jørgensen, citing weight of market pressures
It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with Novo Nordisk's board of directors,
Lars Fruergaard Jørgensen is stepping down as Novo Nordisk CEO, with the company citing its stock's recent struggles.
Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...
The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...
As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for ...
Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...
Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 and was appointed chief executive officer in January 2017. During his ...
Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...
Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback